Association of the Genetic Polymorphisms RRM1 −756T>C and −269C>A With Cervical Neoplasia

Ching Wen Chang, Shun Fa Yang, Po Hui Wang, Hsiu Ju Chang, Wen Chi Liu, Hsiu Ting Tsai

Research output: Contribution to journalArticle

Abstract

Cervical neoplasia is one of the most prevalent malignant neoplasms worldwide. Ribonucleotide reductase 1 (RRM1) is thought to play an essential role in modulating the development and progression of cervical neoplasia. Two novel genetic polymorphisms, RRM1 −756T>C and −269 C>A, are significantly correlated with RRM1 expression. Some epidemiological studies have demonstrated that genetic variants play a crucial role in susceptibility to cervical cancer. The present study aimed to identify the genetic polymorphisms RRM1 −756T>C and −269 C>A in patients with cervical neoplasia and healthy controls. In total, 493 subjects, comprising 324 healthy controls and 169 patients with cervical neoplasia, were enrolled for this study. The allelic discrimination of the RRM1 −756T>C (rs11030918) and −269C>A (rs12806698) polymorphisms was assessed using the ABI StepOne™ real-time polymerase chain reaction system and analyzed using Software Design Specification (SDS), Version 3.0, software with TaqMan assays. The risk of cervical cancer was examined, revealing adjusted odds ratios and 95% confidence intervals of 1.25 [0.51, 3.08] and 1.09 [0.43, 2.78] for individuals with CC alleles of RRM1 −756T>C and for individuals with AA alleles of RRM1 −269C>A genetic polymorphisms, respectively, compared to individuals with wild-type RRM1 genetic polymorphisms. No significant genetic interaction effect was observed in susceptibility to cervical neoplasia, and no association was found between genetic polymorphisms and clinical statuses of invasive cervical cancer. The genetic polymorphisms RRM1 −756T>C and −269C>A may not be a factor for susceptibility to cervical neoplasia.

Original languageEnglish
Pages (from-to)567-572
Number of pages6
JournalBiological Research for Nursing
Volume18
Issue number5
DOIs
Publication statusPublished - Oct 1 2016

Fingerprint

Genetic Polymorphisms
Neoplasms
Uterine Cervical Neoplasms
Alleles
Software Design
Ribonucleotide Reductases
Real-Time Polymerase Chain Reaction
Epidemiologic Studies
Software
Odds Ratio
Confidence Intervals

Keywords

  • cervical neoplasia
  • ribonucleotide reductase 1 (RRM1)
  • RRM1 −269 C > A
  • RRM1 −756T>C
  • single nucleotide polymorphism (SNP)

ASJC Scopus subject areas

  • Research and Theory

Cite this

Association of the Genetic Polymorphisms RRM1 −756T>C and −269C>A With Cervical Neoplasia. / Chang, Ching Wen; Yang, Shun Fa; Wang, Po Hui; Chang, Hsiu Ju; Liu, Wen Chi; Tsai, Hsiu Ting.

In: Biological Research for Nursing, Vol. 18, No. 5, 01.10.2016, p. 567-572.

Research output: Contribution to journalArticle

@article{1755cf26b0bb437da73cc00a3408600a,
title = "Association of the Genetic Polymorphisms RRM1 −756T>C and −269C>A With Cervical Neoplasia",
abstract = "Cervical neoplasia is one of the most prevalent malignant neoplasms worldwide. Ribonucleotide reductase 1 (RRM1) is thought to play an essential role in modulating the development and progression of cervical neoplasia. Two novel genetic polymorphisms, RRM1 −756T>C and −269 C>A, are significantly correlated with RRM1 expression. Some epidemiological studies have demonstrated that genetic variants play a crucial role in susceptibility to cervical cancer. The present study aimed to identify the genetic polymorphisms RRM1 −756T>C and −269 C>A in patients with cervical neoplasia and healthy controls. In total, 493 subjects, comprising 324 healthy controls and 169 patients with cervical neoplasia, were enrolled for this study. The allelic discrimination of the RRM1 −756T>C (rs11030918) and −269C>A (rs12806698) polymorphisms was assessed using the ABI StepOne™ real-time polymerase chain reaction system and analyzed using Software Design Specification (SDS), Version 3.0, software with TaqMan assays. The risk of cervical cancer was examined, revealing adjusted odds ratios and 95{\%} confidence intervals of 1.25 [0.51, 3.08] and 1.09 [0.43, 2.78] for individuals with CC alleles of RRM1 −756T>C and for individuals with AA alleles of RRM1 −269C>A genetic polymorphisms, respectively, compared to individuals with wild-type RRM1 genetic polymorphisms. No significant genetic interaction effect was observed in susceptibility to cervical neoplasia, and no association was found between genetic polymorphisms and clinical statuses of invasive cervical cancer. The genetic polymorphisms RRM1 −756T>C and −269C>A may not be a factor for susceptibility to cervical neoplasia.",
keywords = "cervical neoplasia, ribonucleotide reductase 1 (RRM1), RRM1 −269 C > A, RRM1 −756T>C, single nucleotide polymorphism (SNP)",
author = "Chang, {Ching Wen} and Yang, {Shun Fa} and Wang, {Po Hui} and Chang, {Hsiu Ju} and Liu, {Wen Chi} and Tsai, {Hsiu Ting}",
year = "2016",
month = "10",
day = "1",
doi = "10.1177/1099800416649051",
language = "English",
volume = "18",
pages = "567--572",
journal = "Biological Research for Nursing",
issn = "1099-8004",
publisher = "SAGE Publications Inc.",
number = "5",

}

TY - JOUR

T1 - Association of the Genetic Polymorphisms RRM1 −756T>C and −269C>A With Cervical Neoplasia

AU - Chang, Ching Wen

AU - Yang, Shun Fa

AU - Wang, Po Hui

AU - Chang, Hsiu Ju

AU - Liu, Wen Chi

AU - Tsai, Hsiu Ting

PY - 2016/10/1

Y1 - 2016/10/1

N2 - Cervical neoplasia is one of the most prevalent malignant neoplasms worldwide. Ribonucleotide reductase 1 (RRM1) is thought to play an essential role in modulating the development and progression of cervical neoplasia. Two novel genetic polymorphisms, RRM1 −756T>C and −269 C>A, are significantly correlated with RRM1 expression. Some epidemiological studies have demonstrated that genetic variants play a crucial role in susceptibility to cervical cancer. The present study aimed to identify the genetic polymorphisms RRM1 −756T>C and −269 C>A in patients with cervical neoplasia and healthy controls. In total, 493 subjects, comprising 324 healthy controls and 169 patients with cervical neoplasia, were enrolled for this study. The allelic discrimination of the RRM1 −756T>C (rs11030918) and −269C>A (rs12806698) polymorphisms was assessed using the ABI StepOne™ real-time polymerase chain reaction system and analyzed using Software Design Specification (SDS), Version 3.0, software with TaqMan assays. The risk of cervical cancer was examined, revealing adjusted odds ratios and 95% confidence intervals of 1.25 [0.51, 3.08] and 1.09 [0.43, 2.78] for individuals with CC alleles of RRM1 −756T>C and for individuals with AA alleles of RRM1 −269C>A genetic polymorphisms, respectively, compared to individuals with wild-type RRM1 genetic polymorphisms. No significant genetic interaction effect was observed in susceptibility to cervical neoplasia, and no association was found between genetic polymorphisms and clinical statuses of invasive cervical cancer. The genetic polymorphisms RRM1 −756T>C and −269C>A may not be a factor for susceptibility to cervical neoplasia.

AB - Cervical neoplasia is one of the most prevalent malignant neoplasms worldwide. Ribonucleotide reductase 1 (RRM1) is thought to play an essential role in modulating the development and progression of cervical neoplasia. Two novel genetic polymorphisms, RRM1 −756T>C and −269 C>A, are significantly correlated with RRM1 expression. Some epidemiological studies have demonstrated that genetic variants play a crucial role in susceptibility to cervical cancer. The present study aimed to identify the genetic polymorphisms RRM1 −756T>C and −269 C>A in patients with cervical neoplasia and healthy controls. In total, 493 subjects, comprising 324 healthy controls and 169 patients with cervical neoplasia, were enrolled for this study. The allelic discrimination of the RRM1 −756T>C (rs11030918) and −269C>A (rs12806698) polymorphisms was assessed using the ABI StepOne™ real-time polymerase chain reaction system and analyzed using Software Design Specification (SDS), Version 3.0, software with TaqMan assays. The risk of cervical cancer was examined, revealing adjusted odds ratios and 95% confidence intervals of 1.25 [0.51, 3.08] and 1.09 [0.43, 2.78] for individuals with CC alleles of RRM1 −756T>C and for individuals with AA alleles of RRM1 −269C>A genetic polymorphisms, respectively, compared to individuals with wild-type RRM1 genetic polymorphisms. No significant genetic interaction effect was observed in susceptibility to cervical neoplasia, and no association was found between genetic polymorphisms and clinical statuses of invasive cervical cancer. The genetic polymorphisms RRM1 −756T>C and −269C>A may not be a factor for susceptibility to cervical neoplasia.

KW - cervical neoplasia

KW - ribonucleotide reductase 1 (RRM1)

KW - RRM1 −269 C > A

KW - RRM1 −756T>C

KW - single nucleotide polymorphism (SNP)

UR - http://www.scopus.com/inward/record.url?scp=84987725356&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84987725356&partnerID=8YFLogxK

U2 - 10.1177/1099800416649051

DO - 10.1177/1099800416649051

M3 - Article

C2 - 27179014

AN - SCOPUS:84987725356

VL - 18

SP - 567

EP - 572

JO - Biological Research for Nursing

JF - Biological Research for Nursing

SN - 1099-8004

IS - 5

ER -